A Phase 3 interventional study of Placebo and Brivaracetam in Epilepsy, sponsored by UCB Pharma SA. Completed at 76 sites in 12 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-21.
Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 8th largest by enrollment, is one of 3 that started in 2007, is one of 21 in phase 3, and was the 9th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2007.
This study's enrollment of 399 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma SA, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma SA is the lead sponsor of 28 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 21st largest by enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2007, is one of 74 in phase 3, and was the 34th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Matching Placebo tablets administered twice a day
Other: Placebo
Brivaracetam 20 mg/day, 10 mg administered twice a day
Drug: Brivaracetam
Brivaracetam 50 mg/day, 25 mg administered twice a day
Drug: Brivaracetam
Brivaracetam 100 mg/day, 50 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.
Time frame: From Baseline to 12-week Treatment Period
Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period
Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week. The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a \>= 50 % reduction in seizure frequency per week from Baseline.
Time frame: From Baseline to 12-week Treatment Period
All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period
There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III).
Time frame: From Baseline to 12-week Treatment Period
Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week
The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) \* 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction.
Time frame: From Baseline to 12-week Treatment Period
Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period
The categories are: * \<= 25 % * - 25 % to \< 25 % * 25 % to \< 50 % * 50 % to \< 75 % * 75 % to \< 100 % * 100 %
Time frame: From Baseline to 12-week Treatment Period
Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period
Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.
Time frame: From Baseline to 12-week Treatment Period
Time to First Type I Seizure During the 12-week Treatment Period
The time to first Type I Seizure during the 12-week Treatment Period was measured in days.
Time frame: From Baseline to 12-week Treatment Period
Time to Fifth Type I Seizure During the 12-week Treatment Period
The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days.
Time frame: From Baseline to 12-week Treatment Period
Time to Tenth Type I Seizure During the 12-week Treatment Period
The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days.
Time frame: From Baseline to 12-week Treatment Period
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Hospital Depression Score
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.
Time frame: From Baseline to 12-week Treatment Period
Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit
The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: "Overall, has there been a change in your seizures since the start of the study medication?"
Time frame: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit
The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: "Assess the Overall change in the severity of patient's illness, compared to start of study medication."
Time frame: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline to 12-week Treatment Period
This study started to enroll subjects in September 2007 and concluded in February 2009.
| Milestone | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Started | 100 | 99 | 100 | 100 |
| Completed | 92 | 93 | 88 | 94 |
| Not completed | 8 | 6 | 12 | 6 |
| Withdrew: Ae, non-serious non-fatal | 3 | 4 | 4 | 5 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 0 |
| Withdrew: Other reason | 0 | 1 | 3 | 1 |
| Withdrew: Ae, serious fatal | 1 | 0 | 0 | 0 |
| Withdrew: Serious adverse event (sae), non-fatal | 0 | 0 | 1 | 0 |
| Withdrew: Ae of unknown type | 0 | 0 | 2 | 0 |
Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.
| Seizure Frequency per Week | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period | 1.75 (0.76 to 5.12) | 1.34 (0.70 to 3.12) | 1.49 (0.69 to 2.78) | 1.26 (0.52 to 2.93) |
Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week. The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a \>= 50 % reduction in seizure frequency per week from Baseline.
| Percentage of Participants | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Non-responders | 80.0 | 72.7 | 72.7 | 64.0 |
| Responders | 20.0 | 27.3 | 27.3 | 36.0 |
There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III).
| Times per week | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period | 1.75 (0.76 to 5.61) | 1.34 (0.70 to 3.12) | 1.49 (0.69 to 2.78) | 1.26 (0.52 to 2.93) |
The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) \* 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction.
| Percent change in seizures per week | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week | -17.03 (-40.27 to 17.59) | -30.03 (-55.99 to -2.11) | -26.83 (-60.05 to 6.32) | -32.45 (-72.51 to 0.04) |
The categories are: * \<= 25 % * - 25 % to \< 25 % * 25 % to \< 50 % * 50 % to \< 75 % * 75 % to \< 100 % * 100 %
| Percentage of Participants | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| <= 25 % | 19.0 | 10.1 | 15.2 | 10.0 |
| - 25 % to < 25 % | 41.0 | 35.4 | 33.3 | 33.0 |
| 25 % to < 50 % | 20.0 | 27.3 | 24.2 | 21.0 |
| 50 % to < 75 % | 12.0 | 18.2 | 17.2 | 14.0 |
| 75 % to < 100 % | 8.0 | 7.1 | 9.1 | 18.0 |
| 100 % | 0 | 2.0 | 1.0 | 4.0 |
Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.
| Percentage of Participants | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Seizure free | 0 | 2.0 | 0 | 4.0 |
| No Seizures but non-completer | 0 | 0 | 1.0 | 0 |
| Not Seizure-free | 100.0 | 98.0 | 99.0 | 96.0 |
The time to first Type I Seizure during the 12-week Treatment Period was measured in days.
| Days | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Time to First Type I Seizure During the 12-week Treatment Period | 4 (3 to 5) | 6 (3 to 8) | 6 (4 to 10) | 4 (3 to 5) |
The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days.
| Days | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Time to Fifth Type I Seizure During the 12-week Treatment Period | 19 (14 to 25) | 25 (20 to 34) | 24 (20 to 32) | 24 (18 to 34) |
The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days.
| Days | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Time to Tenth Type I Seizure During the 12-week Treatment Period | 39 (24 to 50) | 49 (36 to 64) | 40 (33 to 49) | 46 (34 to 66) |
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.
| percentage of participants | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period. | 45.9 | 47.2 | 62.5 | 41.0 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 2.29 ± 14.03 | 4.50 ± 12.71 | 3.09 ± 14.43 | 1.78 ± 13.95 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 8.25 ± 22.01 | 6.23 ± 17.97 | 5.34 ± 23.81 | 8.04 ± 26.26 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | -2.09 ± 20.26 | 3.35 ± 19.72 | 3.09 ± 20.79 | 3.50 ± 22.52 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score | -1.54 ± 3.89 | -0.59 ± 3.89 | -0.41 ± 3.82 | 0.08 ± 3.60 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Hospital Depression Score | -0.65 ± 3.58 | -0.10 ± 3.67 | 0.26 ± 3.84 | -0.24 ± 3.69 |
The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: "Overall, has there been a change in your seizures since the start of the study medication?"
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit | 4.93 ± 1.39 | 5.17 ± 1.27 | 5.04 ± 1.29 | 5.47 ± 1.16 |
The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: "Assess the Overall change in the severity of patient's illness, compared to start of study medication."
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit | 4.78 ± 1.20 | 4.99 ± 1.15 | 4.99 ± 1.10 | 5.34 ± 1.12 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 3.49 ± 19.22 | 3.53 ± 17.04 | 1.95 ± 20.74 | 1.99 ± 20.42 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 3.80 ± 18.71 | 3.75 ± 15.94 | 3.13 ± 19.35 | -2.45 ± 18.55 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 1.80 ± 19.16 | 5.36 ± 20.69 | 1.02 ± 19.95 | 0.69 ± 16.66 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 0.92 ± 28.93 | 3.64 ± 29.24 | -0.85 ± 24.36 | 3.00 ± 28.22 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 5.11 ± 18.48 | 4.52 ± 16.73 | 4.55 ± 18.93 | 2.24 ± 18.45 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score | 6.6 ± 16.3 | 6.9 ± 20.1 | 9.7 ± 19.8 | 4.9 ± 18.1 |
Collected over Adverse Events (AEs) were collected up to 23 weeks from Visit 1 (Week -8) to the Safety Visit (Week 15).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 6/100 (6%) | 22/100 (22%) |
| Brivaracetam 20 mg/Day | — | 2/99 (2%) | 31/99 (31.3%) |
| Brivaracetam 50 mg/Day | — | 4/99 (4%) | 35/99 (35.4%) |
| Brivaracetam 100 mg/Day | — | 2/100 (2%) | 37/100 (37%) |
| Event | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| ConvulsionNervous system disorders | 3/100 | 0/99 | 1/99 | 0/100 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/100 | 1/99 | 0/99 | 0/100 |
| AmnesiaPsychiatric disorders | 0/100 | 0/99 | 1/99 | 0/100 |
| Gastritis erosiveGastrointestinal disorders | 0/100 | 0/99 | 1/99 | 0/100 |
| Grand mal convulsionNervous system disorders | 0/100 | 0/99 | 1/99 | 0/100 |
| Jaw fractureInjury, poisoning and procedural complications | 0/100 | 1/99 | 0/99 | 0/100 |
| Psychotic DisorderPsychiatric disorders | 0/100 | 0/99 | 1/99 | 0/100 |
| Vaginal hemorrhageReproductive system and breast disorders | 0/100 | 1/99 | 0/99 | 0/100 |
| Angina pectorisCardiac disorders | 1/100 | 0/99 | 0/99 | 0/100 |
| Humerus fractureInjury, poisoning and procedural complications | 0/100 | 0/99 | 0/99 | 1/100 |
| Event | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day |
|---|---|---|---|---|
| HeadacheNervous system disorders | 10/100 | 14/99 | 18/99 | 9/100 |
| NasopharyngitisInfections and infestations | 1/100 | 8/99 | 1/99 | 2/100 |
| SomnolenceNervous system disorders | 6/100 | 8/99 | 6/99 | 8/100 |
| FatigueGeneral disorders | 2/100 | 3/99 | 4/99 | 8/100 |
| VertigoEar and labyrinth disorders | 3/100 | 1/99 | 2/99 | 8/100 |
| DizzinessNervous system disorders | 5/100 | 5/99 | 7/99 | 5/100 |
| NauseaGastrointestinal disorders | 4/100 | 0/99 | 1/99 | 6/100 |
| ConvulsionNervous system disorders | 1/100 | 5/99 | 1/99 | 2/100 |
| IrritabilityPsychiatric disorders | 0/100 | 0/99 | 5/99 | 1/100 |
Baseline Characteristics refer to the Randomized Set.
| Age, Continuous(years) | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day | Total Title |
|---|---|---|---|---|---|
| Mean | 36.4 ± 13.0 | 35.7 ± 12.5 | 39.0 ± 13.5 | 38.0 ± 13.1 | 37.24 ± 13.05 |
| Age, Customized(participants) | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day | Total Title |
|---|---|---|---|---|---|
| <18 years | 2 | 2 | 0 | 1 | 5 |
| Between 18 and 65 years | 96 | 94 | 97 | 96 | 383 |
| >=65 years | 2 | 3 | 3 | 3 | 11 |
| Sex: Female, Male(Participants) | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day | Total Title |
|---|---|---|---|---|---|
| Female | 46 | 38 | 45 | 42 | 171 |
| Male | 54 | 61 | 55 | 58 | 228 |
| Region of Enrollment(Participants) | Placebo | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Brivaracetam 100 mg/Day | Total Title |
|---|---|---|---|---|---|
| Hungary | 4 | 2 | 3 | 3 | 12 |
| Poland | 26 | 28 | 27 | 27 | 108 |
| India | 23 | 22 | 23 | 23 | 91 |
| Belgium | 3 | 0 | 3 | 0 | 6 |
| Finland | 3 | 3 | 1 | 4 | 11 |
| France | 17 | 17 | 11 | 15 | 60 |
| Germany | 8 | 10 | 14 | 9 | 41 |
| Italy | 4 | 8 | 3 | 5 | 20 |
| Netherlands | 3 | 0 | 1 | 3 | 7 |
| Spain | 8 | 4 | 6 | 4 | 22 |
| Switzerland | 1 | 3 | 6 | 5 | 15 |
| United Kingdom | 0 | 2 | 2 | 2 | 6 |
The record gives a start of Sep 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 7 years 2 months after primary completion. A results delay was requested in Feb 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam